ASH - Multiple Myeloma Research Foundation

ASH 2017

The American Society of Hematology (ASH) is the world's largest professional society of clinicians and scientists working to conquer blood diseases. Its 59th annual meeting — the premier event in hematology — will include more than 30 important abstracts presented by the MMRF.

LIVE FROM ASH

December 12, 2017

ASH 2017 - Day Four

Another ASH meeting has come to a close, but not without another exciting development in MM! This morning’s late-breaking abstract session (abstracts that highlight exciting and substantive studies with a high clinical impact) included data on the use of the monoclonal antibody Darzalex (daratumumab), which has been shown... Read More

December 11, 2017

ASH 2017 - Day Three

Dr. James Kochenderfer from the NIH presented the latest data on the anti-B-cell maturation antigen (BCMA) CAR-T cell therapy bb2121 (ABSTRACT 740). In his Phase 1 study of bb2121 in 21 patients with relapsed/refractory MM (many who had previously received 3 to 14 different regimens), Dr. Kochenderfer and colleagues showed... Read More

December 10, 2017

ASH 2017 - Day Two

Three more abstracts from this morning’s sessions used the MMRF’s CoMMpass data! Gene expression patterns are identified (Abstract 325) and new genes identified (Abstract 326) that are implicated in multiple myeloma development. Read More

December 9, 2017

ASH 2017 - Day One

Two key abstracts were included in this morning’s myeloma session that used data from the MMRF CoMMpass Study to expand our understanding of myeloma patients’ specific genomic profiles (Abstracts 60 and 61). Read More

December 8, 2017

MMRF Recognizes Three Outstanding Organizations at 59th ASH Annual Meeting

The Multiple Myeloma Research Foundation (MMRF) announced at the 59th ASH Annual Meeting the recipients of its awards for outstanding acceleration, innovation and collaboration to advance the research and development of novel therapies for multiple myeloma. Read More

December 8, 2017

MMRF Precision Medicine Model Drives New Discoveries in Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced new discoveries driven by its precision medicine model into the disease drivers, patient subpopulations, and potential therapies for multiple myeloma. Thirty-three research presentations presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta from December 9-12 are wholly or partly enabled by the MMRF’s end-to-end model. The new analyses include 24 presentations on the MMRF CoMMpass StudySM—the largest and most comprehensive study driving new genomic insights and accelerating precision medicine in multiple myeloma—as well as findings from ongoing translational and clinical research efforts. Read More

  • PATIENT RESOURCES

    Multiple Myeloma Highlights from the 2017 ASH Meeting

    Join expert Drs. Faith E. Davies and David Siegel for an exciting discussion on the latest clinical advances in multiple myeloma today.

    Free Webinar
    Wednesday, January 10, 2018 1:00pm – 2:00pm ET

    REGISTER NOW

    2017 Webinar Recordings Available on Our Website

    Access any of these recorded webinars to learn more about these topics:

    • 2-Part Caregiver Series: Ups and Downs; Stem Cell Transplantation
    • 2-Part Meeting Highlights Series: IMW 2017; ASCO/EHA 2017
    • 3-Part Immunotherapy Series: Monoclonal Antibodies; Vaccines; Engineered Cells
    • 3-Part Hot Topics Series: MRD; Maintenance Therapy; Precision Medicine
    VIEW NOW
  • PROFESSIONAL RESOURCES

    my MMRF

    December 8, 2017 Satellite Symposium

    Preceding the 59th American Society of Hematology (ASH) Annual Meeting & Exposition

    MMRF ASH FSS, Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

    View Slides

ABSTRACTS Our abstracts reflect significant progress. Read them here.

Read Accelerator, the semi-annual magazine of the MMRF.

Learn about noteworthy initiatives and other news for MMRF stakeholders.